CT-2576

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameCT-2576
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-2 inhibitorsT lymphocytes inhibitorsImmunosuppressants
TargetsInterleukin-2
Therapy Area/IndicationsRejection of organ transplantationLupus Erythematosus, SystemicNephritis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCti Biopharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCti Biopharma Corp
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationLupus Erythematosus, SystemicNephritis +[6] 

Other Information

ATC CodeN/A
Related LinksN/A